Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease.

Mirza MS.

ISRN Gastroenterol. 2011;2011:592404. doi: 10.5402/2011/592404. Epub 2011 Aug 28.

2.

Non alcoholic fatty liver disease and metabolic syndrome.

Paschos P, Paletas K.

Hippokratia. 2009 Jan;13(1):9-19.

3.

Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis.

Basaranoglu M, Neuschwander-Tetri BA.

Gastroenterol Hepatol (N Y). 2006 Apr;2(4):282-291.

4.

Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.

Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM.

Obesity (Silver Spring). 2009 Sep;17(9):1696-701. doi: 10.1038/oby.2009.89. Epub 2009 Apr 9.

5.

Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.

Pacifico L, Bezzi M, Lombardo CV, Romaggioli S, Ferraro F, Bascetta S, Chiesa C.

World J Gastroenterol. 2013 Jul 7;19(25):4007-14. doi: 10.3748/wjg.v19.i25.4007.

6.

Nonalcoholic fatty liver disease and metabolic syndrome in postmenopausal women.

Rodrigues MH, Bruno AS, Nahas-Neto J, Santos ME, Nahas EA.

Gynecol Endocrinol. 2014 May;30(5):325-9. doi: 10.3109/09513590.2013.875992. Epub 2014 Jan 24. Review.

PMID:
24460502
7.

Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Takahashi Y, Soejima Y, Fukusato T.

World J Gastroenterol. 2012 May 21;18(19):2300-8. doi: 10.3748/wjg.v18.i19.2300. Review.

8.

[The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease].

Orlik B, Handzlik G, Olszanecka-Glinianowicz M.

Postepy Hig Med Dosw (Online). 2010 May 7;64:212-9. Review. Polish.

9.

An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Lomonaco R, Chen J, Cusi K.

Ther Adv Endocrinol Metab. 2011 Oct;2(5):211-25. doi: 10.1177/2042018811419157.

10.

Focus on therapeutic strategies of nonalcoholic Fatty liver disease.

Durazzo M, Belci P, Collo A, Grisoglio E, Bo S.

Int J Hepatol. 2012;2012:464706. doi: 10.1155/2012/464706. Epub 2012 Nov 8.

11.

Nonalcoholic fatty liver disease and cardiovascular disease.

Hyogo H, Chayama K, Yamagishi S.

Curr Pharm Des. 2014;20(14):2403-11. Review.

PMID:
23844815
12.

Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Farrell GC, Larter CZ.

Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112. Review.

PMID:
16447287
13.

Antioxidant Mechanisms in Nonalcoholic Fatty Liver Disease.

Liu W, Baker SS, Baker RD, Zhu L.

Curr Drug Targets. 2015;16(12):1301-14. Review.

PMID:
25915484
14.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.

Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.

Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Review.

PMID:
26159280
15.

Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Massoud O, Charlton M.

Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014. Review.

PMID:
29128057
16.

Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.

Dietrich P, Hellerbrand C.

Best Pract Res Clin Gastroenterol. 2014 Aug;28(4):637-53. doi: 10.1016/j.bpg.2014.07.008. Epub 2014 Jul 11. Review.

PMID:
25194181
17.

Nonalcoholic fatty liver disease.

Yu AS, Keeffe EB.

Rev Gastroenterol Disord. 2002;2(1):11-9. Review.

PMID:
12122975
18.

Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.

Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R.

Hepatology. 2012 Sep;56(3):933-42. doi: 10.1002/hep.25739. Epub 2012 Jul 3.

PMID:
22684858
19.

Insulin resistance in nonalcoholic fatty liver disease.

Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G.

Curr Pharm Des. 2010 Jun;16(17):1941-51. Review.

PMID:
20370677
20.

Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.

Lackner C.

Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):223-31. doi: 10.1586/egh.11.8. Review.

PMID:
21476917

Supplemental Content

Support Center